Iris Loew- Friedrich
Executive Vice-President Chief Medical Officer
Immunology
UCB
Ireland
Biography
Prof. Dr. med. Iris Loew-Friedrich is Executive Vice President and Chief Medical Officer, UCB. She provides strategic global leadership for project leadership, world-wide clinical development, medical affairs and global regulatory affairs for UCB’s portfolio of pipeline projects and products. Her mission is to lead UCB’s Development and Medical Practices and help develop patient solutions with proven superior and sustainable value for patients suffering from severe diseases. Dr. Loew-Friedrich also oversees UCB’s Patient Affairs function, which places a strategic focus on better understanding and improving the patient experience in currently underserved medical areas in immunological and neurological diseases. Prior to taking on her current role in March 2008, Dr. Loew-Friedrich was UCB’s Global Head of Development, during which time she oversaw clinical development of key neurology and immunology products. From 2001 to 2009, Dr. Loew-Friedrich also served as the head of Global Research and Development for Schwarz Pharma, which UCB moved to acquire in 2006. She was also on the Schwarz Pharma Executive Board. Dr. Loew-Friedrich held several medical and R&D roles, including Vice- President and Head of Global Projects at BASF Pharma, Ludwigshafen, Germany; Vice-President, Head of Global Clinical Management, HMR/Aventis, and Therapeutic Area Head Rheumatology and Bone Diseases, Hoechst/HMR, Bridgewater, New Jersey
Research Interest
She provides strategic global leadership for project leadership, world-wide clinical development, medical affairs and global regulatory affairs for UCB’s portfolio of pipeline projects and products.
